Landmark Study Reveals Molecular Roadmap of Brain Aging
141 living cortical samples from neurosurgical patients, paired with MRI and multi-omics profiling across more than 100,000 cells, revealed...
Successful Venglustat Phase 3 Trial Offers Hope for Gaucher
Sanofi’s brain-penetrant GCS inhibitor venglustat met the primary endpoint and three of four key secondary endpoints in the Phase...
Venglustat Breakthrough in Phase 3 Gaucher Disease Study
In the Phase 3 LEAP2MONO study (n=43), venglustat achieved statistically significant improvement in neurological function at week 52 versus...
Crinetics Initiates Phase 2/3 Pediatric Trial for CAH
Crinetics’ atumelnant has previously shown statistically significant 12‑week reductions in androstenedione and 17‑hydroxyprogesterone in Phase 2, and the company...
Pioneering Trial: 4D Path Advances Bladder Cancer Biomarkers
4D Path’s QPOR platform has been selected as an exploratory biomarker in the Phase II DAD-IO study (NCT04724018) in...
Aprea WEE1 Inhibitor Trial Shows Early Proof-of-Concept
A single patient with PPP2R1A-mutated uterine serous carcinoma achieved an unconfirmed partial response with a 50% reduction in target...
Breakthrough Study: Red-Light Therapy Offers Hope For Brains
In a randomized, season-long study of 26 NCAA Division I football players, active intranasal and transcranial photobiomodulation with a...
RevMed Doses First Patient in RAS(ON) G12V Inhibitor Trial
Revolution Medicines has dosed the first patient in RMC-5127-001 (NCT07349537), a first-in-human, open-label study of RMC-5127, a selective inhibitor...
Cortigent’s Orion System Shows Promising 6-Year Study Data
In a six-patient Early Feasibility Study with follow-up extending to six years, Cortigent’s Orion visual cortical prosthesis improved performance...
Kymera Announces First Patient Dosed in Asthma Drug Trial
Kymera has begun dosing in BREADTH, a global, randomized, double-blind, placebo-controlled Phase 2b study of KT-621 in approximately 264...